---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-083203"
form_type: "8-K"
ticker: "INM"
cik: "0001728328"
company_name: "InMed Pharmaceuticals Inc."
filed_at: "2024-09-30T23:59:59+00:00"
generated_at: "2026-05-31T00:47:41.174506+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# InMed FY2024 net loss $7.7M; revenue up 11% to $4.6M; cash $6.6M

## Summary
- Net loss of $7.7M vs $7.9M prior year; diluted EPS loss $1.01 vs $3.25.
- Revenue from BayMedica segment $4.6M, up 11% YoY; gross profit $1.1M.
- Cash, equivalents, and short-term investments $6.6M at June 30, 2024.
- R&D and patent expenses $3.8M; G&A $5.3M, down from $5.8M.
- Pipeline update: INM-901 Alzheimer's program advancing; INM-089 dry AMD preclinical data positive.

## SEC filing metadata
- accession: 0001213900-24-083203
- form_type: 8-K
- ticker: INM
- cik: 0001728328
- company_name: InMed Pharmaceuticals Inc.
- filed_at: 2024-09-30T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1728328/000121390024083203/0001213900-24-083203-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1728328/000121390024083203/ea0216150-8k_inmed.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-083203
- JSON: https://secwatch.observer/filing/0001213900-24-083203.json
- Plain text: https://secwatch.observer/filing/0001213900-24-083203.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.